# Ildiko Lingvay

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ildiko-lingvay/

## Facts

| Field | Value |
| --- | --- |
| Citations | 46,981 |
| Field | Diabetes Treatment and Management |
| h-index | 90 |
| i10-index | 201 |
| Last Known Institution | Southwestern Medical Center |
| OpenAlex ID | https://openalex.org/A5001655356 |
| ORCID iD | 0000-0001-7006-7401 |
| Works | 439 |

## Researcher papers

Showing 12 of 20.

- [Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [Once-Weekly Semaglutide in Adults with Overweight or Obesity](https://scholariq.org/papers/once-weekly-semaglutide-in-adults-with-overweight-or-obesity/)
- [Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes](https://scholariq.org/papers/semaglutide-and-cardiovascular-outcomes-in-obesity-without-diabetes/)
- [Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes](https://scholariq.org/papers/oral-semaglutide-and-cardiovascular-outcomes-in-patients-with-type-2-diabetes/)
- [2. Diagnosis and Classification of Diabetes:<i>Standards of Care in Diabetes—2024</i>](https://scholariq.org/papers/2-diagnosis-and-classification-of-diabetes-i-standards-of-care-in-diabetes-2024/)
- [Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial](https://scholariq.org/papers/semaglutide-2-4-mg-once-a-week-in-adults-with-overweight-or-obesity-and-type-2/)
- [2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2025](https://scholariq.org/papers/2-diagnosis-and-classification-of-diabetes-standards-of-care-in-diabetes-2025/)
- [Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity](https://scholariq.org/papers/effect-of-subcutaneous-semaglutide-vs-placebo-as-an-adjunct-to-intensive/)
- [Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <scp>STEP</scp> 1 trial extension](https://scholariq.org/papers/weight-regain-and-cardiometabolic-effects-after-withdrawal-of-semaglutide-the/)
- [Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial](https://scholariq.org/papers/semaglutide-versus-dulaglutide-once-weekly-in-patients-with-type-2-diabetes/)
- [9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025](https://scholariq.org/papers/9-pharmacologic-approaches-to-glycemic-treatment-standards-of-care-in-diabetes/)
- [Cardiac Steatosis in Diabetes Mellitus](https://scholariq.org/papers/cardiac-steatosis-in-diabetes-mellitus/)

## Researcher topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.